Metraipolis › archive › dc_95e1a4f57dd2

Effect of tolvaptan on the prognosis of patients with rapidly progressive autosomal dominant polycystic kidney disease: a prospective open-label study — Europe PMC PMID:41907239

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41907239
DOI
10.3389/fmed.2026.1739751
License (as archived)
solo-consultazione
Archived
2026-11-04T12:33:53.624Z
SHA-256 of the archived text
cb68e98be73d563c40dfde75026125572ea05131c569eca7df0c4830641f905a
Stable URL of this page
https://metraipolis.com/documento/dc_95e1a4f57dd2

How to cite

Effect of tolvaptan on the prognosis of patients with rapidly progressive autosomal dominant polycystic kidney disease: a prospective open-label study — Europe PMC PMID:41907239 — Europe PMC (en), https://europepmc.org/article/MED/41907239 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_95e1a4f57dd2 (Metraipolis archive dc_95e1a4f57dd2, sha256 cb68e98be73d563c40dfde75026125572ea05131c569eca7df0c4830641f905a)
BibTeX
@misc{dc95e1a4f57dd2,
  title = {Effect of tolvaptan on the prognosis of patients with rapidly progressive autosomal dominant polycystic kidney disease: a prospective open-label study — Europe PMC PMID:41907239},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41907239},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_95e1a4f57dd2; sha256 cb68e98be73d563c40dfde75026125572ea05131c569eca7df0c4830641f905a},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41907239. Agents can read the archived copy with the MCP tool read_document.